A global conference showcasing innovative medical research and training advancements in healthcare is set to return to Dublin for a two-day event in 2018. BioPharma Ambition will bring together globally renowned experts to discuss the latest research and developments for the biopharmaceutical industry on 21 and 22 February 2018.
International policy leaders, renowned researchers and senior industry personnel are all expected to attend the multi-platform event that will combine keynote talks, panel discussions and an industry showcase. The line-up of speakers will include representatives from regulatory bodies such as the Health Products Regulatory Authority, as well as David Chesney, former director at the US Food and Drug Administration, and Nathalie Moll, the newly appointed director general of the European Federation of Pharmaceutical Industries and Associations.
Commenting at the launch of the second iteration of the international biopharma industry convention, Matt Moran, director of BioPharmaChem Ireland (BPCI) and one of the founding partners of BioPharma Ambition said: “Currently, more than 28,000 people work within the industry here [in Ireland], but with the right investment from policymakers, we could see that figure rise to more than 36,000 by 2020.
“To remain the global location of choice for the development and manufacturing of biopharmaceuticals, and to help the industry navigate Brexit uncertainty, it is essential that the Government increases investment in education, research and development for our industry. An increase in spending on science, technology and innovation to 2.5 per cent of GDP by 2020 would be an important step in the right direction.”
Pictured at the launch of BioPharma Ambition 2018 are: Oliver O’Connor, Chief Executive of IPHA; Aidan Gough, Acting CEO Intertrade Ireland; Matt Moran, Director of BPCI and Dominic Carolan, CEO of NIBRT.
Photo credit: Conor McCabe Photography.
